We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.